PRL was found to abrogate cisplatin binding to DNA and to increase the sequestration of cisplatin in the cytoplasm by the glutathione-S-transferase8, whereas a PRLR antagonist sensitized T47D breast tumour cells to cisplatin30. The gene discussed is PRL; the disease is breast neoplasm.